Literature DB >> 25628248

Potential use of glioblastoma tumorsphere: clinical credentialing.

Seok-Gu Kang1, Jae-Ho Cheong, Yong Min Huh, Eui Hyun Kim, Sun Ho Kim, Jong Hee Chang.   

Abstract

A decade ago, cancer stem cells (CSCs) were introduced as target cells for an innovative cancer treatment. Particularly, there have been a lot of biological researches on glioblastoma (GBM) CSCs. However, as there is a comprehensive change in the concept of CSCs, it is required to review how the different CSCs for patients can be clinically used, or clinical credentialing, and summarize the possibilities of clinical credentialing. In this regard, this review aims to introduce the tumorsphere obtained from GBM specimen and summarize the clinical dilemma and clinically applicable areas.

Entities:  

Mesh:

Year:  2015        PMID: 25628248     DOI: 10.1007/s12272-015-0564-0

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  12 in total

1.  Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.

Authors:  Junseong Park; Jin-Kyoung Shim; Joon Hee Kang; Junjeong Choi; Jong Hee Chang; Soo-Youl Kim; Seok-Gu Kang
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

2.  A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.

Authors:  Tae Hoon Roh; Ji-Hyun Lee; Seo Jin Kim; Jin-Kyoung Shim; Junseong Park; Seon-Jin Yoon; Wan-Yee Teo; Se Hoon Kim; Jong Hee Chang; Seok-Gu Kang
Journal:  J Neurooncol       Date:  2021-11-22       Impact factor: 4.130

3.  C5α secreted by tumor mesenchymal stem-like cells mediates resistance to 5-aminolevulinic acid-based photodynamic therapy against glioblastoma tumorspheres.

Authors:  Junseong Park; Seung Jae Oh; Jin-Kyoung Shim; Young Bin Ji; Ju Hyung Moon; Eui Hyun Kim; Yong-Min Huh; Jin-Suck Suh; Jong Hee Chang; Su-Jae Lee; Seok-Gu Kang
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-15       Impact factor: 4.322

4.  Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.

Authors:  Eui Hyun Kim; Ji-Hyun Lee; Yoonjee Oh; Ilkyoo Koh; Jin-Kyoung Shim; Junseong Park; Junjeong Choi; Mijin Yun; Jeong Yong Jeon; Yong Min Huh; Jong Hee Chang; Sun Ho Kim; Kyung-Sup Kim; Jae-Ho Cheong; Pilnam Kim; Seok-Gu Kang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

5.  Success of tumorsphere isolation from WHO grade IV gliomas does not correlate with the weight of fresh tumor specimens: an immunohistochemical characterization of tumorsphere differentiation.

Authors:  Kyoung Su Sung; Jin-Kyoung Shim; Ji-Hyun Lee; Se Hoon Kim; Sohee Park; Tae-Hoon Roh; Ju Hyung Moon; Eui-Hyun Kim; Sun Ho Kim; Su Jae Lee; Yong Min Huh; Seok-Gu Kang; Jong Hee Chang
Journal:  Cancer Cell Int       Date:  2016-09-27       Impact factor: 5.722

6.  Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).

Authors:  Junjeong Choi; Ji-Hyun Lee; Ilkyoo Koh; Jin-Kyoung Shim; Junseong Park; Jeong Yong Jeon; Mijin Yun; Se Hoon Kim; Jong In Yook; Eui Hyun Kim; Jong Hee Chang; Sun Ho Kim; Yong Min Huh; Su Jae Lee; Michael Pollak; Pilnam Kim; Seok-Gu Kang; Jae-Ho Cheong
Journal:  Oncotarget       Date:  2016-10-04

7.  Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.

Authors:  Hyeong-Cheol Oh; Jin-Kyoung Shim; Junseong Park; Ji-Hyun Lee; Ran Joo Choi; Nam Hee Kim; Hyun Sil Kim; Ju Hyung Moon; Eui Hyun Kim; Jong Hee Chang; Jong In Yook; Seok-Gu Kang
Journal:  J Cancer Res Clin Oncol       Date:  2020-07-25       Impact factor: 4.553

8.  Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments.

Authors:  Kyung-Min Kim; Jin-Kyoung Shim; Jong Hee Chang; Ji-Hyun Lee; Se-Hoon Kim; Junjeong Choi; Junseong Park; Eui-Hyun Kim; Sun Ho Kim; Yong-Min Huh; Su-Jae Lee; Jae-Ho Cheong; Seok-Gu Kang
Journal:  Cancer Cell Int       Date:  2016-06-10       Impact factor: 5.722

9.  NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.

Authors:  Antonio Lucena-Cacace; Daniel Otero-Albiol; Manuel P Jiménez-García; Javier Peinado-Serrano; Amancio Carnero
Journal:  Oncotarget       Date:  2017-08-28

Review 10.  Glioblastoma Treatments: An Account of Recent Industrial Developments.

Authors:  Edouard Alphandéry
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.